Transcriptomics in Atherosclerosis: Deciphering Molecular Signatures and Advancing Therapeutic Strategies

Yvan Devaux · Miron Sopić

2025년 9월 · Elsevier

eBook

300

페이지

적용 가능

이 책은 2025년 9월 1일에 구매할 수 있으며 출판 전에는 청구되지 않습니다.

eBook 정보

"Transcriptomics in Atherosclerosis: Deciphering Molecular Signatures and Advancing Therapeutic Strategies integrates transcriptomic research and RNA-based therapeutics to understand and treat atherosclerosis, emphasizing the power of genetic insights to revolutionize cardiovascular medicine. This book fills an essential gap by offering up-to-date insights into molecular mechanisms, diagnostic innovations, and therapeutic strategies, fostering a new era of personalized cardiovascular care. Specifically, readers will find information on cutting-edge RNA sequencing methods, clinical translation and multi-omics integration; as well as phenotyping and treatment stratification, complemented by a multi-omics approach to provide a holistic view of vascular pathology. "Transcriptomics in Atherosclerosis: Deciphering Molecular Signatures and Advancing Therapeutic Strategies provides a deep understanding of disease mechanisms and potential interventions. Of great interest to readers will be the focus on RNA-based biomarkers and therapeutics for early detection, monitoring, and targeted interventions in atherosclerosis. Additionally, advanced transcriptomic technologies and their applications presents an illuminating exploration of novel RNA sequencing methods, including single-cell and spatial transcriptomics, and how they unveil the complexities of atherosclerotic disease. This book will doubtlessly be the one reached for by medical professionals seeking edification in this bourgeoning field.• Unravels the molecular intricacies of atherosclerosis using the latest transcriptomic technologies, offering new perspectives on disease mechanisms and potential therapeutic targets• Highlights the transformative potential of RNA molecules in advancing diagnostics and developing novel RNA-based treatments for personalized medicine in cardiovascular care• Provides actionable insights into translating transcriptomic findings into clinical applications, enhancing patient stratification, and treatment strategies

저자 정보

Yvan Devaux’s main research interest and expertise is the discovery and validation of novel RNA biomarkers and therapeutic targets of brain and heart diseases. As his research focus is translational, he believes that collaboration is key: one of his professional goals is to bring together complementary expertise from clinicians, basic researchers, computational biologists, health economists, social sciences and humanities experts, as well as industrial partners to tackle unmet medical needs. His research projects are translational and patient-centered. His team has developed and extensively validated biomarker discovery pipelines based on deep sequencing, bioinformatics approaches, complex statistics, artificial intelligence and machine learning. He is acquainted with coordinating large research projects and consortia. His main current focus is the heart-brain axis and RNA biomarkers of cardiovascular and neurological disease.

Miron Sopić, Ph.D., serves as an Associate Professor in the Department of Medical Biochemistry at the University of Belgrade's Faculty of Pharmacy. His educational contributions span a diverse array of subjects, including General Biochemistry, Biostatistics, and Laboratory Diagnostics, highlighting his broad expertise in the field. Sopić's research endeavors are centered on investigating the intricate interactions between inflammation and oxidative stress in cardiometabolic diseases, with a particular focus on identifying and developing novel RNA biomarkers. His prolific academic output includes more than 41 scientific papers. In 2022, Miron Sopić was honored with the esteemed MSCA Postdoctoral Fellowship, which facilitated his collaboration with Yvan Devaux on researching epitranscriptomic signatures in atherosclerosis at the Cardiovascular Research Unit of the Luxembourg Institute of Health.